More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$7.64B
EPS
-0.02
P/E ratio
--
Price to sales
4.09
Dividend yield
--
Beta
0.277594
Previous close
$46.53
Today's open
$46.37
Day's range
$45.10 - $46.65
52 week range
$27 - $55.67
show more
CEO
Blair Jackson
Employees
2050
Headquarters
Dublin 4,
Exchange
Nasdaq Global Select
Shares outstanding
168043540
Issue type
Common Stock
Healthcare
Pharmaceuticals
Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
Alkermes NASDAQ: ALKS is preparing for a series of clinical readouts across its orexin drug programs, with studies in sleep disorders, attention-deficit/hyperactivity disorder and fatigue expected over the next 12 months, CEO Blair Jackson said during a fireside chat.
MarketBeat • Nov 16, 2026

Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present data from across its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8, 2026 in Colorado Springs, Colo. The company will present data related to LYBALVI® (olanzapine and samidorphan), ARISTADA® (aripiprazole lauroxil) and LUMRYZ® (sodium oxybate) extended-release oral suspension, as well as alixorexton, the company's novel, investigation.
Business Wire • Nov 5, 2026

What Alkermes (ALKS) Said on Its Q3 Earnings Call
Alkermes NASDAQ: ALKS reported third-quarter 2026 results marked by 31% year-over-year growth in proprietary product sales, while management highlighted continued investment in its orexin development portfolio across sleep, neuropsychiatric and neurological disorders.
MarketBeat • Nov 3, 2026

Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript
Alkermes plc ( ALKS ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Blair Jackson - President, CEO & Director Todd Nichols Joshua Reed - Senior VP & CFO Conference Call Participants Leonid Timashev - RBC Capital Markets, Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Rudy Li David Amsellem - Piper Sandler & Co., Research Division David Hoang - Deutsche Bank AG, Research Division Marc Goodman - Leerink Partners LLC, Research Division Alex Nackenoff Umer Raffat - Evercore ISI Institutional Equities, Research Division So Youn Shim - UBS Investment Bank, Research Division Ami Fadia - Needham & Company, LLC, Research Division Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division Douglas Tsao - H.C.
Seeking Alpha • Nov 4, 2026

Alkermes plc Reports Third Quarter 2026 Financial Results
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) today, to discuss these financial results and provide an update on the company. The webcast may be accessed.
Business Wire • Nov 3, 2026

Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.49 per share a year ago.
Zacks Investment Research • Nov 3, 2026

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 3, 2026

Alkermes to Present at Upcoming Investor Conferences
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2026 Healthcare Conference Date/Time: Fireside chat on Tuesday, Nov. 10, 2026 at 10:40 a.m. ET (3:40 p.m. GMT) Jefferies Global Healthcare Conference in London Date/Time: Fireside chat on Wednesday, Nov. 18, 2026 at 11:30 a.m. ET (4:30 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14.
Business Wire • Nov 3, 2026

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in adult participants with major depressive disorder (MDD). ALKS 7290 is the company's investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD) and for the adjunctive treatment of MDD. “Orexin biology represents a compelling are.
Business Wire • Oct 30, 2026

Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story
Alkermes is maintained at a 'Buy' with a $57 price target, driven by LUMRYZ's commercial momentum and a promising neuroscience pipeline. 3Q26 revenue is projected to rise 18% year-over-year but decline sequentially, with adjusted EPS expected to fall 64.3% due to elevated R&D and SG&A expenses. LUMRYZ's patient growth and LYBALVI's prescription trends are key near-term metrics, while Alixorexton's clinical progress bolsters long-term investment appeal.
Seeking Alpha • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Alkermes plc commission-free¹. Build wealth for the long term using automated trading and transfers.